On June 2, 2022, Hilf, Justin A.; Rose, Tristin E.; Bartberger, Michael D.; O’Boyle, Brendan M.; Reeves, Corey M.; Loson, Oliver C.; Stoltz, Brian M.; McDermott, Martina; O’Brien, Neil A.; Slamon, Dennis published a patent.COA of Formula: C12H8N2 The title of the patent was Preparation of substituted N-(spiro[indene-2,7′-quinazolin]-4′-yl)piperazines as Kras G12C inhibitors. And the patent contained the following:
The invention relates to compounds I [x1 = C(O) or C(R1)(R2); x2 = a bond, CO, O, etc.; y1b and y1c = independently C=CH2, CO, O, S, etc.; z1-z4 = independently C and N; R1 and R2 = independently H and F; R3 = independently H, (halo)alkyl; R4-R7 = independently H, F, Cl, Me, etc., R8a = H, alkyl, cycloalkyl, etc.; R8b = H, CN, halo, etc.; with the provisons], and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds I are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation. E.g., a multi-step synthesis of II鈥FA, starting from 5,6,7,8-tetrahydroquinazoline-2,4-diol, was described. Exemplified compounds I were tested for their KRAS G12C inhibitory activity (data given for representative compounds I). Pharmaceutical composition comprising compound I was disclosed. The experimental process involved the reaction of 2-(2,3-Dihydro-1H-inden-1-ylidene)malononitrile(cas: 2510-01-2).COA of Formula: C12H8N2
The Article related to spiroindenequinazolinylpiperazine preparation kras protein g12c mutation inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.COA of Formula: C12H8N2
Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts